placeholder
Importance
62
Trust
80
Urgency
30
REGULATORY · PRIMARY SOURCE
Eden Health International Inc. dba Eden - 728279 - 06/08/2026
The FDA warned Eden Health International for making false claims about its compounded semaglutide and tirzepatide drugs. The company falsely labeled itself as the maker of the drugs and claimed its suppliers were "FDA-licensed," which doesn't exist—the FDA does not formally license compounding pharmacies.
Analysis
FDA is cracking down on telehealth sellers of compounded semaglutide and tirzepatide that use fake credentials. Companies making false 'FDA-licensed' claims risk seizure and sales bans.
- FDA issued warning letter to Eden Health International (Denver, CO) on June 8, 2026
- Eden labeled itself as compounder of semaglutide and tirzepatide products when it is not
- Eden falsely claimed suppliers were 'FDA-licensed 503(a) outsourcing facilities' — no such designation exists
FDA Drug Approvals & Databases4d
Read